-
Analysts Weigh In: Regado Future 'Unclear' As Shares Fall Below Cash Value
Monday, August 25, 2014 - 2:34pm | 206Read More...Regado Biosciences (NASDAQ: RGDO) plunged after safety concerns permanently halted trials on its lead drug candidate for preventing complications from angioplasty surgery. Deutsche Bank's Robyn Karnauskas downgraded the shares to Hold from Buy and slashed her target 87 percent to $2, from $14....
